Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 VitriVax Awarded $9.9M Grant to Scale Up Clinical Manufacturing | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

VitriVax Awarded $9.9M Grant to Scale Up Clinical Manufacturing

The two-year award supports Phase 1-ready GMP manufacturing activities for ALTA technology.

By: Rachel Klemovitch

Assistant Editor

VitriVax, Inc., a vaccine formulation technology company, was awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials.

Within the scope of this grant, VitriVax will work with a Contract Development and Manufacturing Organization (CDMO) suited for early-phase clinical production. The work includes preparation and execution of manufacturing and regulatory activities in support of future clinical development of an ALTA-enabled vaccine.

ALTA is designed to stabilize antigens and adjuvants and enable co-formulation of otherwise incompatible components, to improve vaccine utility, compatibility, and supply resilience. Scale-up and qualification activities of the ALTA technology are intended to de-risk early clinical manufacturing and accelerate timelines from formulation to first-in-human studies.

“This grant enables us to take ALTA from lab-scale innovation to Phase 1-ready GMP manufacturing, an essential step toward broader access to next-generation vaccines,” said Romulo Colindres, Chief Executive Officer of VitriVax. “Building GMP-compliant manufacturing capacity for innovative vaccine technologies is critical to ensuring that safe, effective vaccines can reach people around the globe. By working with a CDMO partner, we are not only preparing for first-in-human clinical studies but also laying the groundwork for scalable, reliable production that supports global public health priorities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics